✦ LIBER ✦

P130 Angiogenic factor levels in bone marrow and serum of multiple myeloma patients are not applicable to predict response to chemotherapy

✍ Scribed by Gy. Vadász; G. Radványi; I. Tárkányi; S. Baráth; M. Udvardy

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 48 KB
Volume: 21
Category: Article
ISSN: 0268-960X
DOI: 10.1016/s0268-960x(07)70208-4

No coin nor oath required. For personal study only.

✦ Synopsis

showed diffuse large B-cell lymphoma. She developed complete remission after treatment with 6 cycles R-CHOP (rituximab, and reduced doses of cyclophosphamide, vincristin, adriablastin, methylprednisolone). SLE became inactive and her symptoms of vasculitis resolved.

Conclusion:

We are bringing attention to one of the possible late complications of systemic lupus, and also underscoring that treatment with rituximab (+CHOP) was beneficial not only for the lymphoma but the SLE as well.

📜 SIMILAR VOLUMES

The combination of intermediate doses of

The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma

✍ E. Hatjiharissi; E. Terpos; M. Papaioannou; C. Hatjileontis; V. Kaloutsi; G. Gal 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB

## Abstract The aim of the study was the evaluation of anti‐angiogenic activity of the combination of intermediate doses of thalidomide and dexamethasone in patients with refractory/relapsed myeloma. Twenty‐five patients were included in the study. Microvessel density (MVD) was evaluated in marrow